Search results for: NICE

Alastair Fischer

30 August 2023

…Institute of Clinical Excellence (NICE) where he remained for 16 years, first in the economic evaluation of drugs and then a longer period in Public Health. His main research interests…

Around The World in HTAs: Türkiye – The bumpy road toward transformation

31 January 2024

…NICE in the UK. This is promising but political will is required to determine the role of HTA in reimbursement decisions. After the establishment of an independent HTA body, an…

Rare Disease Day 2024: Why Do We Care About Rare?

29 February 2024

…in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases – OHE. Office of Health Economics. Published January 9, 2021. Accessed February 27, 2024. https://www.ohe.org/publications/case-study-analysis-challenges-nice-evaluation-multi-indication-medicines-rare-and/ Cole A, Cubi-Molla…

GLP-1 Receptor Agonists: Shifting Obesity Management

12 May 2025

…GLP-1s in the UK? In the UK, as reported within a NICE published news article, GLP-1 receptor agonists are only prescribed when someone has a body mass index (BMI) over…

Impact

…and Care Excellence (NICE) makes recommendations to the NHS about which treatments should be available based on explicit, rigorous health economic analysis and stakeholder engagement. As a result, UK-based researchers…

Incorporating Multiple Criteria in HTA

19 April 2011

…pay for depends, of course, on the health gain that results. Health technology assessment (HTA) and cost-effectiveness analysis have become the core for many such decisions — by NICE in…

Measuring Value with Pharmacoeconomics

26 May 2011

…provinces in Canada.  Since then, the UK has established NICE (1999) and several other European countries  request economic analyses for at least some new medicines, including Belgium, Finland, Ireland, Norway,…

Join OHE for Its 50th Anniversary Annual Lecture with Sir Michael Rawlins

12 April 2012

…the “gold standard”, instead urging a more pragmatic approach. Sir Michael’s experience – as a clinician, chair of the Committee on Safety of Medicines, and chair of NICE — uniquely…

OHE Presents at Two Key Workshops on Use of EQ-5D in HTA Across Asia

27 March 2013

…context of HTA. For additional information, please contact Nancy Devlin.   Application of EQ-5D in Reimbursement Decision Making: The Case of NICE from Office of Health Economics      …